Related Experiment Videos

Carvedilol in the treatment of elderly patients with chronic heart failure

Klaus K A Witte1, Andrew L Clark

  • 1Academic Department of Cardiology, LIGHT Building, University of Leeds and Leeds General Infirmary, UK. klauswitte@hotmail.com

Clinical Interventions in Aging
|May 21, 2008
PubMed

Insights

Adrenergic blockade significantly reduces mortality and hospitalizations in older patients with chronic heart failure (CHF). Despite proven benefits, undertreatment remains an issue in this demographic.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Chronic heart failure (CHF) is a prevalent condition, particularly in aging populations.
  • Adrenergic blockade has demonstrated efficacy in reducing mortality and hospitalizations in CHF patients.
  • Undertreatment of older CHF patients with adrenergic blockade is a significant clinical concern.

Purpose of the Study:

  • To review the mechanisms underlying the benefits of adrenergic blockade in CHF.
  • To analyze clinical data from randomized studies focusing on older CHF patients.
  • To highlight the importance of addressing undertreatment in this population.

Main Methods:

  • Review of existing literature on adrenergic blockade in CHF.
  • Analysis of data from large-scale randomized controlled trials.
  • Focus on studies specifically including elderly participants.

Main Results:

  • Compelling evidence supports reduced mortality and hospitalizations with adrenergic blockade in older CHF patients.
  • Potential mechanisms for these benefits are explored.
  • Clinical trial data reinforce the positive impact of this therapy.

Conclusions:

  • Adrenergic blockade offers significant benefits for older patients with chronic heart failure.
  • Further efforts are needed to improve treatment rates in this age group.
  • Understanding mechanisms and clinical data is crucial for optimizing care.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...